Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Herbst, Roy; Giaccone, Giuseppe; de Marinis, Filippo; Reinmuth, Niels; Vergnenegre, Alain; Barrios, Carlos; Morise, Masahiro; Felip, Enriqueta; Andric, Zoran; Geater, Sarayut; ÖZGÜROĞLU, Mustafa; Zou, Wei; Sandler, Alan; Enquist, Ida; Komatsubara, Kimberly; Deng, Yu; Kuriki, Hiroshi; Wen, Xiaohui; McCleland, Mark; Mocci, Simonetta; Jassem, Jacek; Spigel, David

doi:10.1056/nejmoa1917346

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Herbst R. S., Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C. H., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.14, pp.1328-1339, 2020 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 383 Issue: 14
Publication Date: 2020
Doi Number: 10.1056/nejmoa1917346
Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Page Numbers: pp.1328-1339
Istanbul University Affiliated: No

Abstract

BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.